Please assess the completion status of the following clinical trial:

Trial Title: Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~This study was open to all subjects who:~* Completed participation in LEVP2005-1/A (NCT00289211) and were not participating in LEVP2005-1/B (NCT01005888), any time after the 3-day telephone follow-up~* Completed participation in LEVP2005-1/B any time after the final prophylactic therapy in Part B~* Were enrolled but not randomized in LEVP2005-1/A after Part A was closed~* Were excluded from LEVP2005-1 for any of the following reasons:~  * Pregnancy or lactation~ * Age less than 6 years~ * Narcotic addiction~ * Presence of anti-C1INH autoantibodies~* Were not enrolled in LEVP2005-1 after enrollment in LEVP2005-1 was closed, under the following circumstances:~  * Had a diagnosis of HAE: evidence of a low C4 level plus either a low C1INH antigenic level or a low C1INH functional level, or~ * Had a known HAE-causing C1INH mutation, or~ * Had a diagnosis of HAE based on a strong family history of HAE as determined by the principal investigator~Exclusion Criteria:~* History of allergic reaction to C1INH or other blood products~* Participated in any other investigational drug study within the past 30 days~* Received blood or a blood product in the past 60 days other than C1INH-nf

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-label C1INH-nf (Type: EXPERIMENTAL): 1,000 Units (U) of C1INH-nf administered intravenously. If there was no response to treatment 60 minutes after the first dose, a second 1,000 U dose could be administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).